AZN and BMY Consider $400B Merger in Pharma Tie-Up
TL;DR Summary
AstraZeneca and Bristol-Myers Squibb are reportedly in talks to merge, with a combined value near $400 billion that would create one of the world's largest pharma groups; no deal terms have been disclosed and talks could stall. Such a cross-border deal would face antitrust reviews in the US, UK, and EU, with investors awaiting more detail ahead of the Q3 2026 results in late October.
Topics:business#astrazeneca#bristol-myers-squibb#mergers-acquisitions#mergers-acquisitions-and-takeovers#pharmaceuticals#regulatory-scrutiny
- AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report Yahoo Finance
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports CNBC
- AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says Reuters
- AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up Financial Times
- AstraZeneca Is Said to Have Explored Bristol Myers Merger Bloomberg.com
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
12 min
vs 12 min read
Condensed
97%
2,400 → 65 words
Want the full story? Read the original article
Read on Yahoo Finance